Skip to main content
. 2020 Mar 31;111(5):1478–1490. doi: 10.1111/cas.14374

Figure 2.

Figure 2

Clinically relevant manipulation of anti–GPC3 28bbz QHJI‐iPSC #22 to generate iCAR‐NK/ILC. A, Schematic for differentiation of anti–GPC3 28bbz QHJI‐iPSC #22 into iCAR‐NK/ILC. B, Flow‐cytometric analysis of differentiated cells at the end of the first step. C, Flow‐cytometric analysis of differentiated cells at the end of the second step. D, Cell number of differentiated cells during the second step. E, Flow‐cytometric analysis of differentiated cells at the end of the third step. F, Cell number of iCAR‐NK/ILC during the third step